DCC/HBV治疗性疫苗佐剂有效剂量的初步研究  

The Pilot Study on Effective Dose of DCC/HBV Therapeutic Vaccine Adjuvant

作　　者：董富敏 袁有成 易学瑞 

机构地区：[1]解放军第四五八医院全军肝病中心全军肝病重点实验室,广东广州510600

出　　处：《现代食品与药品杂志》2007年第4期3-5,共3页JOurnal of Modern Food and Pharmaceuticals

基　　金：广东省科技攻关项目(2003C31205)

摘　　要：目的考察新型治疗性乙肝疫苗佐剂的有效剂量。方法DC-Chol/HBsAg免疫Balb/c小鼠,ELISA法测血清特异性抗体IgG1和IgG2 a水平,ELISPOT法检测免疫后小鼠脾细胞经HBsAg刺激后产生IFN-γ的细胞数。结果DC-Chol最低有效剂量在0.063～0.125 mg/只小鼠。结论DCC/HBV治疗性疫苗能同时诱导Balb/c小鼠体液和细胞免疫反应,其佐剂最低有效剂量低于文献报道。Objective To study the effective dose of new HBV therapeutic vaccine adjuvant. Methods After immunized by DC/HB- sAg, IgG1 and IgG2a in Balb/c mice were measured by ELISA method, IFN-γ/cell number was measured by ELISPOT. Results The effective dose of DC-Chol was 0. 063 - 0. 125 mg/mice. Conclusion DCC/HBV therapeutic vaccine can induce both humoral and cellular immunity response in Balb/c mice and the effective dose of DC-Chol adjuvant was lower than previously reported.

关 键 词：DC—Chol ELISA ELISPOT 佐剂 

分 类 号：R965.3[医药卫生—药理学]